CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mersana Therapeutics, Inc., announced today that the U.S. Patent and Trademark Office has granted three new U.S. patents, further strengthening its intellectual property (IP) position in next-generation antibody-drug conjugate (ADC) technologies that utilize the Fleximer® polymer. U.S. Patent No. 8,808,679 provides coverage for anti-tumor payloads and customized linkers utilized in Mersana’s Dolaflexin™ conjugation platform. U.S. Patent No. 8,815,226 expands Mersana’s IP portfolio to encompass Fleximer platform technology that is optimized to create ADCs with antibody alternatives. The third patent, U.S. Patent No. 8,821,850, provides broad coverage for Fleximer-based ADCs and use thereof. Together with U.S. Patent No. 8,685,383, which issued earlier this year, the claims of these patents provide Mersana with expansive IP protection for its innovative, highly differentiated platform technologies.
Help employers find you! Check out all the jobs and post your resume.
